Effectiveness, safety and drug survival of oral roflumilast for hidradenitis suppurativa-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effectiveness, safety and drug survival of oral roflumilast for hidradenitis suppurativa

Published:2024-07 Issue: Volume: Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Holgersen Nikolaj¹^ORCID,Nielsen Valdemar Wendelboe¹,Ring Hans Christian¹,Egeberg Alexander¹²,Thyssen Jacob P.¹²^ORCID,Gyldenløve Mette²³^ORCID,Thomsen Simon Francis¹⁴

Affiliation:

1. Department of Dermato‐Venereology & Wound Healing Centre Copenhagen University Hospital Bispebjerg and Frederiksberg Denmark

2. Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

3. Department of Dermatology and Allergy Copenhagen University Hospital Herlev and Gentofte Denmark

4. Department of Biomedical Sciences University of Copenhagen Copenhagen Denmark

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.20222

Reference6 articles.

1. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD

2. Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO)

3. Considerable improvement in hidradenitis suppurativa with oral roflumilast therapy

4. Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial

5. Orismilast for the treatment of mild to severe hidradenitis suppurativa: Week 16 data from OSIRIS, a Phase 2a, open‐label, single‐centre, single‐arm, dose‐finding clinical trial

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP